Cited by 1,460Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Open access

Johannessen, Cory M., Boehm, Jesse S., Kim, So Young, Thomas, Sapana R., Wardwell, Leslie, Johnson, Laura A., Emery, Caroline M., Stransky, Nicolas, Cogdill, Alexandria P., Barretina, Jordi, Caponigro, Giordano, Hieronymus, Haley, Murray, Ryan R., Salehi-Ashtiani, Kourosh, Hill, David E., Vidal, Marc, Zhao, Jean J., Yang, Xiaoping, Alkan, Ozan, Kim, Sungjoon, Harris, Jennifer L., Wilson, Christopher J., Myer, Vic E., Finan, Peter M., Root, David E., Roberts, Thomas M., Golub, Todd, Flaherty, Keith T., Dummer, Reinhard, Weber, Barbara L., Sellers, William R., Schlegel, Robert, Wargo, Jennifer A., Hahn, William C., Garraway, Levi A.·2010·Nature

DOI 10.1038/nature09627PMC PMC3058384

Open this paper in CoChat — free account

Abstract

Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance. Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09627

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citation
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citation
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 701–800 of 1,002

Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics
Kim, D.-H., & Sim, T. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0403-5 · Cited by 31
Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.
Monsma, D. J., Cherba, D., Eugster, E., Dylewski, D., Davidson, P. J., Peterson, C. A., Borgman, A. S., Winn, M. E., Dykema, K. J., Webb, C. P., et al. (2015) · Europe PMC (PubMed Central) · Cited by 32
Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer
Angus, S. P., Zawistowski, J. S., & Johnson, G. L. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052954 · Cited by 32
RETRACTED ARTICLE: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets
Kanojia, D., Garg, M., Martinez, J., Anand, M. T., Luty, S. B., Doan, N., SAID, J. W., Forscher, C. A., Tyner, J. W., & Koeffler, H. P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0540-x · Cited by 30
Retracted
Pathologic Characteristics of Spitz Melanoma With MAP3K8 Fusion or Truncation in a Pediatric Cohort
Newman, S., Pappo, A. S., Raimondi, S. C., Zhang, J., Barnhill, R. L., & Bahrami, A. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001362 · Cited by 32
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
Wang, H., Lv, Q., Xu, Y., Cai, Z., Zheng, J., Cheng, X., Dai, Y., Janne, P. A., Ambrogio, C., & Köhler, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.012 · Cited by 32
Tumor Progression Locus 2 Mediates Signal-Induced Increases in Cytoplasmic Calcium and Cell Migration
Hatziapostolou, M., Κούκος, Γ., Polytarchou, C., Kottakis, F., Serebrennikova, O. B., Kuliopulos, A., & Tsichlis, P. N. (2011) · Science Signaling · doi:10.1126/scisignal.2002006 · Cited by 34
Identification of TFG (TRK‐fused gene) as a putative metastatic melanoma tumor suppressor gene
Dutton‐Regester, K., Aoude, L. G., Nancarrow, D. J., Stark, M. S., O’Connor, L., Lanagan, C., Pupo, G. M., Tembe, V., Carter, C. D., OʼRourke, M. G. E., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21932 · Cited by 30
LAR protein tyrosine phosphatase regulates focal adhesions through CDK1
Sarhan, A. R., Patel, T. R., Cowell, A. R., Tomlinson, M. G., Hellberg, C. B., Heath, J. K., Cunningham, D. L., & Hotchin, N. A. (2016) · Journal of Cell Science · doi:10.1242/jcs.191379 · Cited by 31
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
McArthur, G. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00161 · Cited by 30
Melanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 30
Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling
Jung, K., Samadani, R., Chauhan, J., Nevels, K. J., Yap, J. L., Zhang, J., Worlikar, S. A., Lanning, M. E., Chen, L., Ensey, M., et al. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40199e · Cited by 30
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
Madhunapantula, S. V., Sharma, A. K., Gowda, R., & Robertson, G. P. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12156 · Cited by 31
The Current State of Targeted Therapy in Melanoma: This Time It's Personal
Smalley, K. S. M., & McArthur, G. A. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.01.008 · Cited by 31
MEK and RAF inhibitors for BRAF-mutated cancers
Belden, S. E., & Flaherty, K. T. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.11 · Cited by 30
Self-citation
Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors
Cooper, J. M., Patel, A. J., Chen, Z., Liao, C.-P., Chen, K., Mo, J., Wang, Y., & Le, L. Q. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2437 · Cited by 29
Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors
Ali, E. M. H., El‐Telbany, R. F. A., Abdel‐Maksoud, M. S., Ammar, U. M., Mersal, K. I., Zaraei, S., El-Gamal, M. I., Choi, S.-I., Lee, K., Kim, H.-K., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113277 · Cited by 30
14-3-3 proteins inactivate DAPK2 by promoting its dimerization and protecting key regulatory phosphosites
Horvath, M., Petrvalská, O., Heřman, P., Obšilová, V., & Obšil, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02518-y · Cited by 30
Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF
Giroux, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.037 · Cited by 30
Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Narita, Y., Okamoto, K., Kawada, M. I., Takase, K., Minoshima, Y., Kodama, K., Iwata, M., Miyamoto, N., & Sawada, K. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0667 · Cited by 31
Targeting 3-phosphoinositide-dependent protein kinase 1 by N-acetyl-cysteine through activation of peroxisome proliferators activated receptor alpha in human lung cancer cells, the role of p53 and p65
Hann, S. S., Zheng, F., & Zhao, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-43 · Cited by 30
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma
Boregowda, R. K., Medina, D. J., Markert, E. K., Bryan, M. A., Chen, W., Chen, S., Rabkin, A., Vido, M. J., Gunderson, S., Chekmareva, M. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8822 · Cited by 31
Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas
Yao, T.-W., Zhang, J., Prados, M., Weiss, W. A., James, C. D., & Nicolaides, T. P. (2016) · Oncotarget · doi:10.18632/oncotarget.11882 · Cited by 30
Interaction of molecular alterations with immune response in melanoma
Sloane, R. A. S., Gopalakrishnan, V., Reddy, S. M., Zhang, X., Reuben, A., & Wargo, J. A. (2017) · Cancer · doi:10.1002/cncr.30681 · Cited by 31
Self-citation
The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
Hanson, K., Robinson, S. D., Al‐Yousuf, K., Hendry, A. E., Sexton, D. W., Sherwood, V., & Wheeler, G. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23378 · Cited by 34
SPRED1 deletion confers resistance to MAPK inhibition in melanoma
Ablain, J., Liu, S., Moriceau, G., Lo, R. S., & Zon, L. I. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201097 · Cited by 33
Systemic therapy of metastatic melanoma: on the road to cure.
Bhatia, S., Tykodi, S. S., Lee, S. M., & Thompson, J. A. (2015) · PubMed · Cited by 30
China tackles surge in mental illness
Cyranoski, D. (2010) · Nature · doi:10.1038/468145a · Cited by 30
Mechanisms of Resistance to RAF Inhibition in Melanomas Harboring a BRAF Mutation
Chapman, P. B. (2013) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2013.33.e80 · Cited by 41
Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.
Jazirehi, A. R., Nazarian, R., Torres‐Collado, A. X., & Economou, J. S. (2014) · Europe PMC (PubMed Central) · Cited by 29
The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma
Zhan, Y., Dahabieh, M. S., Rajakumar, A., Dobocan, M. C., M’Boutchou, M.-N., Gonçalves, C., Lucy, S. L., Pettersson, F., Topisirović, I., van Kempen, L. C. L. T., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.11 · Cited by 29
Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling
Chen, J., Shen, Q. “., Labow, M., & Gaither, L. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3761 · Cited by 29
Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development
Cohen-Solal, K., Kaufman, H. L., & Lasfar, A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12666 · Cited by 30
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
Sanlorenzo, M., Vujic, I., Esteve‐Puig, R., Lai, K., Vujic, M., Lin, K. C., Posch, C., Dimon, M. T., Moy, A., Zekhtser, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27643-3 · Cited by 30
Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment
Erdmann, S., Seidel, D., Jahnke, H., Eichler, M., Simon, J., & Robitzki, A. A. (2019) · Scientific Reports · doi:10.1038/s41598-018-37188-0 · Cited by 29
New treatment options in hairy cell leukemia with focus on BRAF inhibitors
Falini, B., & Tiacci, E. (2019) · Hematological Oncology · doi:10.1002/hon.2594 · Cited by 29
A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma
Jackett, L. A., & Scolyer, R. A. (2019) · Cancers · doi:10.3390/cancers11122041 · Cited by 30
Structure-based mechanism of preferential complex formation by apoptosis signal–regulating kinases
Trevelyan, S. J., Brewster, J. L., Burgess, A. E., Crowther, J. M., Cadell, A. L., Parker, B. L., Croucher, D. R., Dobson, R. C. J., Murphy, J. M., & Mace, P. D. (2020) · Science Signaling · doi:10.1126/scisignal.aay6318 · Cited by 27
When less is more – a fast TurboID knock-in approach for high-sensitivity endogenous interactome mapping
Stockhammer, A., Spalt, C., Klemt, A., Benz, L. S., Harel, S., Natalia, V., Wiench, L., Freund, C., Kuropka, B., & Bottanelli, F. (2024) · Journal of Cell Science · doi:10.1242/jcs.261952 · Cited by 26
A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition
Klein, R. M., & Higgins, P. J. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-114 · Cited by 30
Molecular testing in malignant melanoma
Grossmann, A. H., Grossmann, K. F., & Wallander, M. L. (2012) · Diagnostic Cytopathology · doi:10.1002/dc.22810 · Cited by 28
Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing
Moskalev, E. A., Frohnauer, J., Merkelbach‐Bruse, S., Schildhaus, H., Dimmler, A. W., Schubert, T., Boltze, C., König, H., Fuchs, F. S., Sı̂rbu, H., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.002 · Cited by 28
Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion
Serrano‐Oviedo, L., Ortega‐Muelas, M., García‐Cano, J., Valero, M. L., Cimas, F. J., Pascual‐Serra, R., Fernández‐Aroca, D. M., Roche, O., Ruiz‐Hidalgo, M. J., Belandia, B., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200878 · Cited by 28
Proteomic analysis of desmosomes reveals novel components required for epidermal integrity
Badu-Nkansah, K. A., & Lechler, T. (2020) · Molecular Biology of the Cell · doi:10.1091/mbc.e19-09-0542 · Cited by 27
The utility of transposon mutagenesis for cancer studies in the era of genome editing
DeNicola, G. M., Karreth, F. A., Adams, D. J., & Wong, C. C. (2015) · Genome biology · doi:10.1186/s13059-015-0794-y · Cited by 30
In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAF V600E in melanoma
Guo, X., Xu, Y., & Zhao, Z. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0328-y · Cited by 28
Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin
Prickett, T. D., Zerlanko, B. J., Gartner, J. J., Parker, S. C. J., Dutton‐Regester, K., Lin, J., Teer, J. K., Wei, X., Jiang, J., Program, N. C. S., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.365 · Cited by 30
Vemurafenib (RG67204, PLX4032): A Potent, Selective BRAF Kinase Inhibitor
Patrawala, S. A., & Puzanov, I. J. (2012) · Future Oncology · doi:10.2217/fon.12.31 · Cited by 28
The pharmacogenomics of drug resistance to protein kinase inhibitors
Gillis, N., & McLeod, H. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.008 · Cited by 29
Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK
Lv, X., Ren, Z., Zhou, B., Li, Q., Chu, M., Liu, D.-H., Mo, K., Zhang, L., Yao, X., & Cao, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.002 · Cited by 28
Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
Ahmad, D. A. J., Negm, O. H., Alabdullah, M. L., Mirza, S., Hamed, M. R., Band, V., Green, A. R., Ellis, I. O., & Rakha, E. A. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3967-9 · Cited by 28
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine
Chappell, W. H., Abrams, S. L., Franklin, R. A., LaHair, M. M., Montalto, G., Cervello, M., Martelli, A. M., Nicoletti, F., Candido, S., Libra, M., et al. (2012) · Cell Cycle · doi:10.4161/cc.22786 · Cited by 27
The RAF Inhibitor Paradox Revisited
Cox, A. D., & Der, C. J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.017 · Cited by 27
Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Micel, L. N., Tentler, J. J., Tan, A. C., Selby, H. M., Brunkow, K. L., Robertson, K. M., Davis, S. L., Klauck, P. J., Pitts, T. M., Gangolli, E. A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1012 · Cited by 28
Advances in the management of melanoma: targeted therapy, immunotherapy and future directions
Dean, E. J., & Lorigan, P. C. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.124 · Cited by 27
Differential localization of A-Raf regulates MST2-mediated apoptosis during epithelial differentiation
Rauch, J., Vandamme, D., Mack, B., McCann, B., Volinsky, N., Blanco, A., Gires, O., & Kölch, W. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.2 · Cited by 27
TAOK3 Regulates Canonical TCR Signaling by Preventing Early SHP-1–Mediated Inactivation of LCK
Ormonde, J. V. S., Li, Z., Stegen, C., & Madrenas, J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800284 · Cited by 27
Mapping the Human Kinome in Response to DNA Damage
Owusu, M., Bannauer, P., da Silva, J. F., Mourikis, T. P., Jones, A. G., Májek, P., Caldera, M., Wiedner, M., Lardeau, C.-H., Müller, A. C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.087 · Cited by 25
Playing the Whack-A-Mole Game: ERK5 Activation Emerges Among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2- Targeted Therapy
Tubita, A., Tusa, I., & Rovida, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.647311 · Cited by 27
Global discovery of protein kinases and other nucleotide‐binding proteins by mass spectrometry
Xiao, Y., & Wang, Y. (2014) · Mass Spectrometry Reviews · doi:10.1002/mas.21447 · Cited by 27
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
Adler, A. J., & Vella, A. T. (2012) · OncoImmunology · doi:10.4161/onci.22837 · Cited by 28
Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor
Halsey, C., Gustafson, D. L., Rose, B. J., Wolf-Ringwall, A. L., Burnett, R. C., Duval, D. L., Avery, A. C., & Thamm, D. H. (2014) · BMC Veterinary Research · doi:10.1186/1746-6148-10-105 · Cited by 27
ATM-Mediated DNA Damage Signals Mediate Immune Escape through Integrin-αvβ3–Dependent Mechanisms
Jinushi, M., Chiba, S., Baghdadi, M., Kinoshita, I., Dosaka‐Akita, H., Ito, K., Yoshiyama, H., Yagita∥, H., Uede, T., & Takaoka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2028 · Cited by 27
The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
Lemech, C., Infante, J. R., & Arkenau, H. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011432949 · Cited by 27
Hsp90 as a “Chaperone” of the Epigenome
Isaacs, J. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.09.003 · Cited by 28
The circadian E3 ligase complex SCFFBXL3+CRY targets TLK2
Papp, S. J., Chan, A. B., Vaughan, M. E., Zolboot, N., Perea, V., Huber, A., Kriebs, A., Moresco, J. J., Yates, J. R., & Lamia, K. A. (2019) · Scientific Reports · doi:10.1038/s41598-018-36618-3 · Cited by 27
Identification and Characterization of a Small‐Molecule Inhibitor of Death‐Associated Protein Kinase 1
Wilbek, T. S., Skovgaard, T., Sorrell, F. J., Knapp, S., Berthelsen, J., & Strømgaard, K. (2014) · ChemBioChem · doi:10.1002/cbic.201402512 · Cited by 27
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Richman, J., Martín-Liberal, J., Diem, S., & Larkin, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1044971 · Cited by 27
Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma
Patel, S. P., & Kim, K. B. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.665871 · Cited by 26
Targeting RAF: trials and tribulations
Downward, J. (2011) · Nature Medicine · doi:10.1038/nm0311-286 · Cited by 26
Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth
Hann, S. S., Tang, Q., Zheng, F., Zhao, S., Chen, J., & Wang, Z. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-149 · Cited by 26
ALK Inhibitors, a Pharmaceutical Perspective
Ardini, E., & Galvani, A. P. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00017 · Cited by 26
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma
Yang, H., Kircher, D. A., Kim, K., Grossmann, A. H., VanBrocklin, M. W., Holmen, S. L., & Robinson, J. P. (2017) · Oncogene · doi:10.1038/onc.2016.526 · Cited by 27
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
Vanella, V., Festino, L., Trojaniello, C., Vitale, M. G., Sorrentino, A., Paone, M., & Ascierto, P. A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0827-x · Cited by 27
Evolution of Molecular Targets in Melanoma Treatment
Tran, K. B., Buchanan, C. M., & Shepherd, P. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200130091318 · Cited by 26
Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
Tang, F., Li, S., Liu, D., Chen, J., & Han, C. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.62 · Cited by 25
Tumor progression locus 2 (TPL2) in tumor-promoting Inflammation, Tumorigenesis and Tumor Immunity
Njunge, L. W., Estania, A. P., Guo, Y., Liu, W., & Yang, L. (2020) · Theranostics · doi:10.7150/thno.45848 · Cited by 29
Dabrafenib
Kainthla, R., Kim, K. B., & Falchook, G. S. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_14 · Cited by 27
Generating and Analyzing Fish Models of Melanoma
Patton, E. E., Mathers, M. E., & Schartl, M. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-381320-6.00014-x · Cited by 27
Dabrafenib for treatment of BRAF-mutant melanoma
Falchook, G. S., Kainthla, R., & Kim, K. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s37220 · Cited by 28
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report
Simeone, E., Maio, E. D., Sandomenico, F., Fulciniti, F., Lastoria, S., Aprea, P., Staibano, S., Montesarchio, V., Palmieri, G., Mozzillo, N., et al. (2012) · Journal of Medical Case Reports · doi:10.1186/1752-1947-6-131 · Cited by 26
A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice
Feng, J.-H., Nakagawa‐Goto, K., Lee, K., & Shyur, L. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0973 · Cited by 26
Epigenetic regulation of RTK signaling
Spangle, J. M., & Roberts, T. M. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1546-0 · Cited by 26
Self-citation
Serine-arginine protein kinase 1 (SRPK1) is elevated in gastric cancer and plays oncogenic functions
Xu, X., Wei, Y., Wang, S., Luo, M., & Zeng, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18734 · Cited by 26
EphA2 phosphorylation at Ser897 by the Cdk1/MEK/ ERK/RSK pathway regulates M‐phase progression via maintenance of cortical rigidity
Kaibori, Y., Saito, Y., & Nakayama, Y. (2019) · The FASEB Journal · doi:10.1096/fj.201801519rr · Cited by 26
Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
Olbryt, M., Pigłowski, W., Rajczykowski, M., Pfeifer, A., Student, S., & Fiszer-Kierzkowska, A. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00695-0 · Cited by 27
Current advances and perspectives in the treatment of advanced melanoma
Livingstone, E., Zimmer, L., Vaübel, J., & Schadendorf, D. (2012) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07895.x · Cited by 26
Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of WTBRAF/WTNRAS melanoma cells to vemurafenib
Krayem, M., Journé, F., Wiedig, M., Morandini, R., Salès, F., Awada, A. H., & Ghanem, G. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.021 · Cited by 27
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy
Lau, E., Šedý, J. R., Sander, C., Shaw, M. A., Feng, Y., Scortegagna, M., Claps, G., Robinson, S. E., Cheng, P. F., Srivas, R., et al. (2015) · Oncogene · doi:10.1038/onc.2015.22 · Cited by 27
Self-citation
MAPK pathway inhibition in melanoma: resistance three ways
Wellbrock, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140020 · Cited by 29
Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
Fratangelo, F., Camerlingo, R., Carriero, M. V., Pirozzi, G., Palmieri, G., Gentilcore, G., Ragone, C., Minopoli, M., Ascierto, P. A., & Motti, M. L. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4457 · Cited by 26
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 29
A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
Al‐Akhrass, H., Conway, J. R. W., Poulsen, A. S. A., Paatero, I., Kaivola, J., Padzik, A., Andersen, O. M., & Ivaska, J. (2021) · Oncogene · doi:10.1038/s41388-020-01604-5 · Cited by 25
Clonal analysis and dynamic imaging identify multipotency of individual Gallus gallus caudal hindbrain neural crest cells toward cardiac and enteric fates
Tang, W., Li, Y., Li, A., & Bronner-Fraser, M. E. (2021) · Nature Communications · doi:10.1038/s41467-021-22146-8 · Cited by 25
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance
Dahabieh, M. S., Huang, F., Gonçalves, C., González, R. E. F., Prabhu, S. A., Bolt, A. M., Pietro, E. D., Khoury, E., Heath, J., Xu, Z., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1936932 · Cited by 25
Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects
Chen, J., Li, G., Qin, P., Chen, J., Ye, N., Waddington, J. L., & Zhen, X. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab137 · Cited by 27
Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas
Gelb, T., Pshenichkin, S. P., Rodriguez, O. C., Hathaway, H. A., Grajkowska, E., DiRaddo, J. O., Wróblewska, B., Yasuda, R. P., Albanese, C., Wolfe, B. B., et al. (2014) · Oncogene · doi:10.1038/onc.2014.231 · Cited by 25
Isolation of a Novel Thioflavin S–Derived Compound That Inhibits BAG-1–Mediated Protein Interactions and Targets BRAF Inhibitor–Resistant Cell Lines
Enthammer, M., Papadakis, E. S., Gachet, M. S., Deutsch, M., Schwaiger, S., Kozieł, K., Ashraf, M., Khalid, S., Wolber, G., Packham, G., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0142 · Cited by 24
A MultiSite Gateway Toolkit for Rapid Cloning of Vertebrate Expression Constructs with Diverse Research Applications
Fowler, D. K., Stewart, S., Seredick, S. D., Eisen, J. S., Stankunas, K., & Washbourne, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159277 · Cited by 22
Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma
Chen, C. Y., & Tang, H. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80150 · Cited by 26

Authors: Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C., & Garraway, L. A.
Affiliations: Broad Institute (US)
Harvard University (US)
Massachusetts General Hospital (US)
Genomics Institute of the Novartis Research Foundation (US)
Dana-Farber Cancer Institute (US)
University of Zurich (CH)
Corresponding author: Garraway, Levi A.
ORCID: Johannessen, Cory M.
Boehm, Jesse S.
Kim, So Young
Stransky, Nicolas
Cogdill, Alexandria P.
Barretina, Jordi
Hill, David E.
Vidal, Marc
Zhao, Jean J.
Yang, Xiaoping
Alkan, Ozan
Wilson, Christopher J.
Myer, Vic E.
Root, David E.
Roberts, Thomas M.
Golub, Todd
Flaherty, Keith T.
Dummer, Reinhard
Weber, Barbara L.
Sellers, William R.
Wargo, Jennifer A.
Hahn, William C.
Garraway, Levi A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-11-24
Volume: 468
Issue: 7326
Pages: 968-972
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09627
PMC: PMC3058384
OpenAlex: W2141674733
Cited by: 1,460
References: 30
Citations by year: 2026: 19 · 2025: 27 · 2024: 32 · 2023: 55 · 2022: 45 · 2021: 56 · 2020: 67 · 2019: 91 · 2018: 78 · 2017: 102 · 2016: 107 · 2015: 121 · 2014: 158 · 2013: 186 · 2012: 177
FWCI: 65.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Funders: National Institutes of Health (DP2OD002750)
National Cancer Institute (RC2CA148268, R01CA134502, K08CA115927, CA134502, R33CA128625, P50CA093683)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: MAP3K8, BRAF inhibitor resistance, vemurafenib, melanoma, BRAF V600E mutation, MAPK signaling
MeSH terms: Vemurafenib, Allosteric Regulation, Clinical Trials as Topic, Enzyme Activation, Humans, Indoles, Melanoma, Proto-Oncogene Proteins, Sulfonamides, Gene Library, Gene Expression Regulation, Neoplastic, Open Reading Frames, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-raf, Gene Expression Profiling, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks